The U S. Government has rights in this invention by virtue of National Cancer Institute Grant No. CA-15472; CA-28900; and CA-14051.
Entry |
---|
Hatcher, V. B., et al. (1978) J. Immunol. 120, 665-670. |
"Effects of N"-Tosyl-1-Lysyl-Chloromethylketone on the Activity of Cytotoxic T Lymphocytes.sup.1 ", by Tse Wen Chang and Herman N. Eisen, J. Immunol., 124, 1028-1033, (1980). |
"The Mechanism of Cell-Mediated Cytotoxicity", by Doug Redelman and Dorothy Hudig, J. Immunol. 124, 870-878 (1980). |
"Inhibition of Human Natural Cytotoxicity by Macromolecular Antiproteases'", by D. Hudig et al., J. Immunol. 126, 1569-1574 (1981). |
"Studies on the Mechanism of NK Cell Lysis'", by P-C. Quan et al., J. Immunol. 128, 1786-1791 (1982). |
"The Requirement for Proteinase Activity for Human Lymphocyte-Mediated Natural Cytotoxicity (NK) Evidence that the Proteinase is Serine Dependent and has Aromatic Amino Acid Specificity of Cleavage.sup.1 ", by D. Hudig et al. J. Immunol 133 2647-2654 (1984). |
"The Site of Action of N-.alpha.-Tosyl-1-Lysyl-Chloromethyl-Ketone (TLCK) on Cloned Cytotoxic T. Lymphocytes'", by M. S. Pasternack et al., J. Immunol. 131, 2477-2483 (1983). |
"Cyclical Changes in Susceptibility of a Myeloma Tumor (LPC-1) /to Immune Destruction", by E. Celis et al. J. Immunol. 122, 954-958 (1979). |